Beyond Biotech Podcast: Natural Killer Cells
Artiva Biotherapeutics’ CEO, Fred Aslan, M.D. was featured on the Beyond Biotech Podcast hosted by Labiotech.eu to discuss recent milestones including:
- Demonstrating the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials, and
- Receiving FDA clearance for an IND for lupus – marking a first for an allogeneic, off-the-shelf NK or CAR-T cell therapy in autoimmune disease.
AlloNK (also known as AB-101) is a non-genetically modified, cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers in the outpatient setting.
Listen to the podcast here.